Form 4: DexCom EVP Michael Jon Brown Disposes of Shares Under 10b5-1 Plan
SEC Form 4
DexCom's EVP and Chief Legal Officer, Michael Jon Brown, sold 629 shares of common stock at $126.25 per share under a pre-arranged 10b5-1 trading plan.
Summary
- Michael Jon Brown, EVP and Chief Legal Officer of DexCom Inc., disposed of 629 shares of common stock on April 30, 2024.
- The transaction was executed at a price of $126.25 per share.
- The sale was conducted under a pre-arranged 10b5-1 trading plan adopted on December 15, 2022, and amended on August 29, 2023.
- Following the transaction, Brown beneficially owns 68,212 shares of DexCom common stock.
- This total includes 60,303 unvested restricted stock units and 159 shares purchased through the employee stock purchase plan.
Sentiment
Score: 6
Explanation: The document is neutral in tone, simply reporting a transaction. The sale is pre-planned, reducing any negative sentiment. The executive still holds a significant number of shares.
Industry Context
Executive stock sales are a common occurrence, especially when executed under pre-arranged trading plans like 10b5-1 plans. These plans allow insiders to sell shares over a period of time, mitigating concerns about trading on non-public information. The market typically views these sales in the context of the executive's overall holdings and the company's performance.
Comparison to Industry Standards
- Executive compensation practices, including the use of restricted stock units and 10b5-1 trading plans, are common across publicly traded companies, particularly in the technology and healthcare sectors.
- Companies like Medtronic, Abbott, and Boston Scientific, which operate in similar spaces, also utilize stock-based compensation and allow executives to establish trading plans.
- The vesting schedules and terms of restricted stock units are generally in line with industry standards, designed to incentivize long-term performance and retention.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders, but given the pre-arranged nature of the sale and the relatively small number of shares involved, the impact is likely to be minimal.
- Employees may be interested in executive stock transactions, but the 10b5-1 plan context should alleviate concerns about insider information.
Key Dates
| Date | Description |
|---|---|
| December 15, 2022 | Mr. Brown adopted a 10b5-1 Plan |
| August 29, 2023 | Amendment to the 10b5-1 Plan |
| March 8, 2022 | Grant date for 24,080 restricted stock units vesting through March 8, 2026 |
| March 8, 2023 | Grant date for 14,512 restricted stock units vesting through March 8, 2026 |
| March 8, 2024 | Grant date for 21,711 restricted stock units vesting through March 8, 2027 |
| April 30, 2024 | Date of stock sale transaction |
| May 02, 2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.